These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 16968579

  • 1. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
    van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM.
    Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
    [Abstract] [Full Text] [Related]

  • 2. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [Abstract] [Full Text] [Related]

  • 4. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S, Olson M, van Staa TP.
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [Abstract] [Full Text] [Related]

  • 5. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [Abstract] [Full Text] [Related]

  • 6. Fracture outcomes related to persistence and compliance with oral bisphosphonates.
    Gallagher AM, Rietbrock S, Olson M, van Staa TP.
    J Bone Miner Res; 2008 Oct; 23(10):1569-75. PubMed ID: 18505366
    [Abstract] [Full Text] [Related]

  • 7. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of bisphosphonate therapy in a community setting.
    Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N.
    Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
    [Abstract] [Full Text] [Related]

  • 9. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y.
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P.
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P, Hamdy NA, Zwinderman AH, Ballieux BE, Papapoulos SE.
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [Abstract] [Full Text] [Related]

  • 14. Factors contributing to compliance with osteoporosis medication.
    Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA, Schousboe JT, Cline RR, Weiss TW.
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F.
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Compliance with drug therapies for the treatment and prevention of osteoporosis.
    McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J.
    Maturitas; 2004 Jul 15; 48(3):271-87. PubMed ID: 15207894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.